Risankizumab scored best for biologic-naïve and biologic-exposed patients in induction of remission but infliximab came out ahead for all patients, according to a report in Gut.
Risankizumab scored best for biologic-naïve and biologic-exposed patients in induction of remission but infliximab came out ahead for all patients, according to a report in Gut.
Risankizumab scored best for...